[1] 边树伟,周志安,张杰,等.2型糖尿病非酒精性脂肪性肝病患者血清脂联素及内脂素的变化及其临床意义的研究.中国糖尿病杂志,2015,23:131-134.
[2] Wang Y, Li YY, Nie YQ, et al. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease.Exp Ther Med,2013,6:77-84.
[3] 非酒精性脂肪性肝病诊疗指南.中华医学会肝病学分会脂肪肝和酒精性肝病学组.中华肝脏病杂志,2010,18:163-166.
[4] van der Poorten D,George J.Current and novel therapies for the treatment of nonalcoholic steatohepatitis.Hepatol Int,2007,1:343-354.
[5] 李运红,徐肇敏,吕瑛,等.胰岛素抵抗与非酒精性脂肪肝的关系研究.南京医科大学学报(自然科学版),2008,28:787-789.
[6] 刘洋,郑绘霞,梁建芳.Nesfatin-1在非酒精性脂肪肝病患者血清中的表达及意义.山西医科大学学报,2015,46:108-110.
[7] Day CP,James OF.Steatohepatitis:a tale of two “hits”? Gastroenterology,1998,114:842-845.
[8] 武绍梅,马岚青.非酒精性脂肪性肝病发病机制及治疗进展.医学综述,2014, 20:4455-4458.
[9] 余小虎,朱金水,邱夏地,等.水飞蓟素联合二甲双胍治疗肥胖型非酒精性脂肪肝的临床研究.实用肝脏病杂志,2005,8:269-271.
[10] Hardy T,Anstee QM,Day CP.Nonalcoholic fatty liver disease:new treatments.Curr Opin Gastroenterol,2015,31:175-183.
[11] 姜健,莫莉,郭建东.CK-18(M30)和胰岛素抵抗指数在非酒精性脂肪性肝病CT分级检测中的意义.标记免疫分析与临床,2015,22:31-33.
[12] Mishra A,Younossi ZM.Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.J Clin Exp Hepatol,2012,2:135-144. |
